1975PubMedRequires access

[Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)].

H Warnatz, F Scheiffarth, Wolfgang Friedrich Gutmann

Open publisher page 1 citations

Abstract

In a controlled trial including 80 patients suffering from different stages of rheumatoid arthritis it was demonstrated that D-penicillamine therapy favourably influences the clinical course of the disease as compared to a control group treated with antirheumatic drugs. Particularly the therapy continued over one year resulted in a significant fall of the joint and activity index as well as of the BSR. Side effects were observed in more than half of the cases. Renal, hematological and severe exanthematic complications forced to discontinue the administration of D-penicillamine in 6 of 41 cases. As compared to other therapeutics our study indicates that D-penicillamine and gold treatment are equivalent drugs in rheumatoid arthritis whereas immunosuppressive drugs are reserved for severe cases of rheumatoid arthritis because of their strong side effects.

About this research paper

What this paper is about

In a controlled trial including 80 patients suffering from different stages of rheumatoid arthritis it was demonstrated that D-penicillamine therapy favourably influences the clinical course of the disease as compared to a control group treated with antirheumatic drugs. Particularly the therapy continued over one year resulted in a significant fall of the joint and activity index as well as of the BSR. Side effects were observed in more than half of the cases. Renal, hematological and severe exanthematic complications forced to discontinue the administration of D-penicillamine in 6 of 41 cases. As compared to other therapeutics our study indicates that D-penicillamine and gold treatment are equivalent drugs in rheumatoid arthritis whereas immunosuppressive drugs are reserved for severe cases of rheumatoid arthritis because of their strong side effects.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

In a controlled trial including 80 patients suffering from different stages of rheumatoid arthritis it was demonstrated that D-penicillamine therapy favourably influences the clinical course of the disease as compared to a control group treated with antirheumatic drugs. Particularly the therapy continued over one year resulted in a significant fall of the joint and activity index as well as of the BSR. Side effects were observed in more than half of the cases. Renal, hematological and severe exanthematic complications forced to discontinue the administration of D-penicillamine in 6 of 41 cases. As compared to other therapeutics our study indicates that D-penicillamine and gold treatment are equivalent drugs in rheumatoid arthritis whereas immunosuppressive drugs are reserved for severe cases of rheumatoid arthritis because of their strong side effects.

Key concepts: Medicine, Penicillamine, Rheumatoid arthritis, Gold salts, Antirheumatic drugs, Internal medicine, Surgery, Antirheumatic Agents

Related papers

Back to paper searchBrowse research topicsOriginal source
[Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)]. — Research Paper | ScholarLens